Hemophilia Treatment Market was valued at US $ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US $ 44,089.71 million by 2027 .
Hemophilia is a condition where the blood does not clot, and this condition is normally inherited. The condition is due to defects in a gene on the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in men because the X chromosome is inherited from mother to baby. The disease is widely treated with replacement therapy and gene therapy. The other treatment used is medication. However, there are ways to reduce the risk of disease including regular exercise and others. The disease can be prevented by taking preventive treatment with an injection of coagulation factor VIII for hemophilia A, or IX for hemophilia B.
Get sample PDF from to @ https://www.theinsightpartners.com/sample/TIPRE00008241/
List of companies in the hemophilia treatment market
Bayer AG
Sanofi
F. Hoffmann-la Roche Ltée.
Kedrion S.P.A.
CSL Limited
Biotest AG
Pfizer Inc.
Novo Nordisk A / S
Octapharma SA
Baxter International Inc.
Global Hemophilia Treatment Market – By Treatment Type
On demand
Prophylaxis
Global Hemophilia Treatment Market – By Therapy
Replacement therapy
ITI therapy
Genetical therapy
Antibody therapy
Global Hemophilia Treatment Market – By End User
Hospitals
Clinics
Outpatient surgical centers
Others
Market information
Increased prevalence of hemophilia
Hemophilia is an inherited bleeding disorder that prevents the blood from clotting normally. The main symptom is uncontrolled, often spontaneous bleeding in different areas of the body. According to data from the National Hemophilia Foundation in 2020, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times more common than hemophilia B. The number of people with hemophilia in the United States is expected to be around 20,000 people. In addition, the incidence of hemophilia is not known worldwide but projected to more than 400,000 people. Almost 75% of people with hemophilia worldwide go undiagnosed or receive disparate treatment.
In Italy, according to data from the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from around 7,000 in 2000 to around 8,500 in 2011 and more. from 11,000 in 2015. The trend is due to an upsurge in the number of registered patients, mainly those with type 1 von Willebrand disease, mild hemophilia or other factor deficiencies.
Having our reports will help you solve the following problems: –
1. Uncertainty about the future?
➟ Our research and knowledge helps our clients predict future revenue pockets and areas of growth. This helps our clients to invest or divest their resources.
2. Understand the market sentiment?
➟ Having a good understanding of market sentiment is imperative for a strategy. Our information provides you with an overview of market sentiment. We maintain this observation by engaging with key thought leaders in a value chain in every industry we track.
3. Understand the most reliable investment centers?
➟ Our research ranks the market’s investment centers taking into account their returns, future demands and profit margins. Our clients can focus on the most important investment centers by sourcing our market research.
4. Evaluate potential business partners?
➟Our research and knowledge helps our customers identify compatible business partners.
Note: Access an in-depth study with over 150 pages, a list of tables and figures, profiling over 10 companies.
Purchase a copy of this report from: https://www.theinsightpartners.com/buy/TIPRE00008241/
About Us :
The Insight Partners is a one-stop-shop for industrial research in actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We are a specialist in Life Sciences, Technology, Health, Manufacturing, Automotive & Defense, Food Drink, Chemistry, etc.
Contact :
Call: + 1-646-491-9876
Email: [email protected]
–
